Scores of oncological experts came together ... Summarial media commentary praised the “ground breaking”, “off the charts”, and “extremely impressive” range of data revealed in ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...

Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US. The Japanese pharma expects its lead product co-developed with ...

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

Leqembi is expensive out of pocket, with costs cited as high as $26,500 per year. However, you don’t need to pay as much under Medicare. Afterward, it pays for 80% of the cost. So, once you meet ...

Opinions expressed by Forbes Contributors are their own. Hugh McIntyre covers music, with a focus on the global charts. Blackpink singer Rosé recently scored one of the biggest hits by any solo ...

The pharmaceutical segment saw a 5% increase, driven by the company's three global brands—Lenvima, Dayvigo, and LEQEMBI—which collectively generated over JPY 200 billion. Despite a decline in ...

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024 ...